AbbVie Inc.
ABBVBusiness Overview
ticker: ABBV step: 01 generated: 2026-05-11 source: quick-research
AbbVie Inc. (ABBV) — Business Overview
Business Description
AbbVie is a global research-based biopharmaceutical company spun off from Abbott Laboratories in 2013. Its business is anchored by immunology (Skyrizi + Rinvoq + Humira), with sizable franchises in neuroscience, oncology, aesthetics (Allergan's Botox + Juvederm), and eye care. After successfully navigating the largest patent cliff in pharma history (Humira, peak $21.2B sales in 2022), AbbVie's combined Skyrizi + Rinvoq sales exceeded $25B in 2025 and are tracking to >$31B by 2027 — already surpassing peak Humira.
Revenue Model
- Immunology (~45% of revenue): Skyrizi (IL-23), Rinvoq (JAK), residual Humira (TNF) — fast-growing replacements offsetting Humira biosimilar erosion
- Oncology (~10%): Imbruvica (BTK, partnered with J&J), Venclexta, Epkinly, Elahere
- Neuroscience (~14%): Vraylar, Botox Therapeutic, Ubrelvy, Qulipta — growing 17%+ annually
- Aesthetics (~9%): Botox Cosmetic, Juvederm, CoolSculpting (acquired via Allergan 2020)
- Eye Care (~6%): Restasis, Xen, Vuity (presbyopia)
- Other (~16%): Mavyret (HCV), Creon, Hytrin
Products & Services
- Skyrizi (risankizumab): IL-23 inhibitor for psoriasis, psoriatic arthritis, Crohn's, ulcerative colitis — $17.6B in 2025 ($21.5B 2026E)
- Rinvoq (upadacitinib): JAK1 inhibitor for RA, psoriatic arthritis, atopic dermatitis, IBD, vitiligo (filed) — $8.3B in 2025 ($10.1B 2026E)
- Humira (adalimumab): Legacy TNF inhibitor, now ~$2.9B/year and shrinking ~40% annually post-LOE
- Botox / Juvederm: Aesthetics franchise from $63B Allergan acquisition (2020)
- Vraylar: Atypical antipsychotic for bipolar, depression
- Vylept: New Parkinson's drug (FDA approved 2026)
- Pipeline: Tirvapadone (Parkinson's, Phase 3), Entantamig (multiple myeloma, Phase 3), Crohn's combo platform
Customer Base & Go-to-Market
- Patients: Millions globally, often with chronic disease (autoimmune, oncology)
- Prescribers: Specialist physicians (rheumatology, dermatology, gastroenterology, neurology, oncology)
- Payers: US PBMs/insurers, ex-US single-payer systems negotiate aggressively
- Aesthetics channel: Direct to dermatologists and plastic surgeons; consumer awareness via DTC marketing
- Geographic mix: ~75% US revenue, ~25% International
Competitive Position
AbbVie has the most successful biopharma post-LOE transition on record — Skyrizi and Rinvoq combined have already surpassed peak Humira. Moats include (1) strong specialty sales force relationships in immunology, (2) scientifically differentiated mechanisms (IL-23 + JAK selective JAK1), (3) Allergan aesthetics distribution franchise, and (4) capital allocation discipline using free cash flow for tuck-in M&A (ImmunoGen, Cerevel) to refresh pipeline. Competes with J&J (Stelara, Tremfya), Eli Lilly (Olumiant, Omvoh), Bristol-Myers (Sotyktu), Pfizer (Xeljanz), Roche (Vabysmo) across therapy areas.
Key Facts
- Founded: 2013 (spin off from Abbott Labs)
- Headquarters: North Chicago, IL
- Employees: ~55,000
- Exchange: NYSE
- Sector / Industry: Health Care / Pharmaceuticals
- Market Cap: ~$365B (May 2026)
- CEO: Rob Michael (succeeded Richard Gonzalez 2024)
- Dividend: ~$6.59 annual; 52+ consecutive years (counting Abbott history) — Dividend King via predecessor lineage
Financial Snapshot
ticker: ABBV step: 04 generated: 2026-05-11 source: quick-research
AbbVie Inc. (ABBV) — Financial Snapshot
Income Statement Summary
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $54.3B | $56.3B | $61.2B | +8.6% |
| Adj. Gross Margin | 84% | 84% | 84% | flat |
| Adj. Operating Margin | 47% | 46% | 47% | +1pp |
| Adj. Net Income | $21.5B | $20.5B | $22.4B | +9% |
| Adj. EPS (diluted) | $11.11 | $10.61 | $12.20 | +15% |
Product Sales (FY2025 vs FY2024)
| Drug | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Skyrizi | $11.7B | $17.6B | +50% |
| Rinvoq | $6.0B | $8.3B | +39% |
| Humira | $9.0B | $5.5B | -39% |
| Skyrizi + Rinvoq combined | $17.7B | $25.9B | +46% |
| Total Immunology | ~$27B | ~$32B | +18% |
| Imbruvica | $3.1B | $2.9B | -7% |
| Vraylar (neuroscience) | $3.0B | $3.5B | +17% |
| Botox Cosmetic | $2.7B | $2.8B | +4% |
Q1 2026 Highlights
| Metric | Q1 2026 | YoY |
|---|---|---|
| Total Revenue | ~$13.5B | +12.4% |
| Skyrizi | $4.48B | +30.9% |
| Rinvoq | ~$2.4B | +20% |
| Humira | $688M | -39% |
Cash Flow & Balance Sheet (FY2025)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$22B |
| Capital Expenditures | ~($1.0B) |
| Free Cash Flow | ~$21B |
| Cash & Equivalents | ~$5B |
| Total Debt | ~$67B (post Allergan/ImmunoGen/Cerevel) |
| Net Debt / EBITDA | ~2.0x (declining) |
Key Ratios (approximate, May 2026)
- P/E (forward): ~14x | EV/EBITDA: ~13x | Dividend Yield: ~3.2%
- ROIC: ~14% | FCF/Net Income conversion: ~95%
Growth Profile
2025 was the inflection year: total revenue +8.6%, with Skyrizi (+50%) and Rinvoq (+39%) more than offsetting Humira (-39%). Management guides 2026 revenue to $67B (+9.5%) and EPS to $14.37-14.57. Combined Skyrizi+Rinvoq guidance raised to >$31B by 2027 (vs. prior $27B), implying 19% organic CAGR despite Humira running off to ~$2B/year. Aesthetics segment softening (consumer discretionary headwind) but immunology + neuroscience more than offsetting.
Forward Estimates
- 2026E Revenue: $67B (mgmt guide; +9.5%)
- 2026E Adj EPS: $14.37-14.57 (mgmt guide)
- 2027E Revenue: ~$73B (consensus)
- 2027E Adj EPS: ~$16
- Skyrizi 2027 target: >$20B (raised from $17B)
- Rinvoq 2027 target: >$11B (raised from $10B)
Capital Return
- Dividend $6.59/share annual = ~$11.5B paid
- 52+ years of consecutive dividend growth (counting Abbott predecessor)
- Modest buybacks (~$2B/year) given priority on debt paydown post-Allergan
- Total return: ~3.2% dividend yield + buybacks + 9%+ FCF growth
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $ABBV.